Conception.bio develops fertility treatments by turning a person’s blood cells into mature egg cells using induced pluripotent stem cell (iPSC) technology. Blood is collected, reprogrammed into iPSCs, and guided to become viable eggs that can be used for reproduction, with optional genetic screening of embryos. It differentiates itself by producing patient-derived eggs from blood and selling directly to consumers, bypassing traditional clinic pathways. The goal is to broaden access to fertility options by enabling later-life parenting and embryo genetic screening through a patient-derived egg platform with a direct-to-consumer model.
Company Size
51-200
Company Stage
Early VC
Total Funding
$20M
Headquarters
Berkeley, California
Founded
2017
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?